Trial Profile
Cabozantinib Plus Durvalumab in Patients With Advanced and Chemotherapy-treated Bladder Carcinoma, of Urothelial and Non-urothelial Histology: an Open-label, Single-centre, Phase 2, Single-arm Proof-of-concept Trial: ARCADIA Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Durvalumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Neuroendocrine tumours; Squamous cell cancer; Urogenital cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms ARCADIA
- 27 Jan 2024 Results investigating if plasma EV immune profile, size and concentration in concert with plasma proteomics might discriminate responding from non-responding patients affected by advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) undergoing cabozantinib (CABO) plus Durvalumab (DURVA) combination therapy after platinum chemotherapy, presented at the 2024 Genitourinary Cancers Symposium
- 27 Jan 2024 Preliminary Results (n=65) assessing Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab presented at the 2024 Genitourinary Cancers Symposium
- 24 Oct 2023 Interim results (n=71) from ARACADIA study presented at the 48th European Society for Medical Oncology Congress